Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/90899
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Keefe, D. | - |
dc.contributor.author | Elting, L. | - |
dc.contributor.author | Nguyen, H. | - |
dc.contributor.author | Grunberg, S. | - |
dc.contributor.author | Aprile, G. | - |
dc.contributor.author | Bonaventura, A. | - |
dc.contributor.author | Selva-Nayagam, S. | - |
dc.contributor.author | Barsevick, A. | - |
dc.contributor.author | Koczwara, B. | - |
dc.contributor.author | Sonis, S. | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Cancer Chemotherapy and Pharmacology, 2014; 74(4):675-680 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.issn | 1432-0843 | - |
dc.identifier.uri | http://hdl.handle.net/2440/90899 | - |
dc.description.abstract | BACKGROUND: Diarrhea is a common toxicity of chemotherapy, but the practice of reporting only severe grades (≥ 3) in clinical trials results in misleading conclusions of significance. Epidemiology remains poorly described, and effects of multi-cycle regimens have not been investigated. To better understand the risks, symptom burden and consequences of CID, we studied patients receiving chemotherapy for colorectal cancer (CRC). METHODS: One hundred and fourteen patients receiving FOLFOX (95 patients, 530 cycles), FOLFOX + monoclonal antibodies (10 patients, 49 cycles) or FOLFIRI (9 patients, 50 cycles) were enrolled. CID was identified from diaries at baseline and daily during up to 8 chemotherapy cycles using supplemental questions on the Oral Mucositis Daily Questionnaire, a valid tool for collecting patient-reported outcomes of regimen-related mucosal injury. Patients scored CID severity from 0 "none" to 10 "worst possible," and quantity from "little" to "severe" on a 5-point scale. Quality of life was measured using the FACT-G, and fatigue using the FACIT fatigue scale. RESULTS: CID occurred in 89% of patients on FOLFIRI, 50% on FOLFOX + monoclonal antibodies and 56% on FOLFOX alone. The risk of a first episode was highest during Cycle 1 (35 %) and dropped to <10% during Cycles 3-5. Patients with CID reported poorer quality of life scores than those without CID (77.1 vs 80.7). CONCLUSIONS: Diarrhea occurs more commonly than typically appreciated during chemotherapy for CRC. Risk is highest during first exposure, suggesting variable susceptibility. Identification of this high-risk subgroup for prophylaxis could improve the quality of life. | - |
dc.description.statementofresponsibility | Dorothy M. Keefe, Linda S. Elting, Hoang T. Nguyen, Steven M. Grunberg, Giuseppe Aprile, Antony Bonaventura, Sudarsha Selva-Nayagam, Andrea Barsevick, Bogda Koczwara, and Stephen T. Sonis | - |
dc.language.iso | en | - |
dc.publisher | Springer Berlin Heidelberg | - |
dc.rights | © Springer-Verlag Berlin Heidelberg 2014 | - |
dc.source.uri | http://dx.doi.org/10.1007/s00280-014-2526-5 | - |
dc.subject | Chemotherapy-induced diarrhea; Chemotherapy; Colorectal cancer; Patient-reported outcomes; Quality of life | - |
dc.title | Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1007/s00280-014-2526-5 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Keefe, D. [0000-0001-9377-431X] | - |
Appears in Collections: | Aurora harvest 2 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.